POSTER PRESENTATION

Open Access

Use of cellular immunotherapy for treatment of refractory acute myeloid leukemia

Loren Fast*, John Reagan, Peter Quesenberry

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

A previous clinical trial carried out by our group in which high numbers of haploidentical donor lymphoid cells containing CD3+ cells ($1 - 2 \times 10^8$ CD3+ cells/kg) were infused into recipients with refractory hematological malignancy found that 14/27 patients gave a response, 9 of which were major. These recipients rapidly developed a cytokine storm which was resolved, if needed, by administering steroids. No persisting donor cells could be detected at 2 weeks following infusion. After gaining FDA and IRB approval, this cellular immunotherapy trial was restarted. One of the goals of the trial was to define the effector mechanisms that were playing a role in anti-leukemic responses. The results from the first recipient enrolled indicated that right after the infusion, 11.3% of peripheral blood mononuclear cells were donor cells as defined by donor-specific anti-HLA antibodies. Donor cell levels had decreased to 0.95% on day 7. Increased expression of granzymes and perforin by both donor and recipient cells especially 2 - 3 days after infusion indicated that these cells exhibited increased cytolytic activity. In addition, both donor and recipient CD4+ cells were found to express increased levels of CD134, and a large fraction of CD8+ cells expressed CD279 (PD-1). The role of cytolytic cells will be assessed further as additional patients are enrolled and the expression of activating or inhibitory receptors will be confirmed. These results could suggest additional therapeutic approaches to be tested for enhancing the anti-leukemic responses following cellular immunotherapy.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P7

Cite this article as: Fast et al.: Use of cellular immunotherapy for treatment of refractory acute myeloid leukemia. *Journal for ImmunoTherapy of Cancer* 2013 **1**(Suppl 1):P7.

Medicine, Rhode Island Hospital, Providence, RI, USA

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

© 2013 Fast et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.